ORGO Organogenesis Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORGO

Price (delayed)

$2.49

Market cap

$328.59M

P/E Ratio

62.25

Dividend/share

N/A

EPS

$0.04

Enterprise value

$343.6M

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's ...

Highlights
ORGO's equity is up by 4.9% YoY
ORGO's debt is down by 3.6% year-on-year and by 2.8% since the previous quarter
The net income has plunged by 68% YoY and by 62% from the previous quarter
The EPS has dropped by 67% year-on-year and by 60% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.organogenesis.com
Peers: OPTN OPK

Key stats

What are the main financial stats of ORGO
Market
Shares outstanding
131.96M
Market cap
$328.59M
Enterprise value
$343.6M
Valuations
Price to earnings (P/E)
62.25
Price to book (P/B)
1.18
Price to sales (P/S)
0.75
EV/EBIT
27.31
EV/EBITDA
9.54
EV/Sales
0.79
Earnings
Revenue
$433.14M
EBIT
$12.58M
EBITDA
$36.03M
Free cash flow
$6.55M
Per share
EPS
$0.04
Free cash flow per share
$0.05
Book value per share
$2.11
Revenue per share
$3.3
TBVPS
$3.17
Balance sheet
Total assets
$460.03M
Total liabilities
$181.36M
Debt
$119.35M
Equity
$278.66M
Working capital
$144.54M
Liquidity
Debt to equity
0.43
Current ratio
2.8
Quick ratio
2.31
Net debt/EBITDA
0.42
Margins
EBITDA margin
8.3%
Gross margin
75.4%
Net margin
1.1%
Operating margin
2.9%
Efficiency
Return on assets
1.1%
Return on equity
1.8%
Return on invested capital
3.5%
Return on capital employed
3.3%
Return on sales
2.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORGO stock price

How has the Organogenesis Holdings stock price performed over time
Intraday
-0.8%
1 week
8.73%
1 month
-4.6%
1 year
30.37%
YTD
-39.12%
QTD
-12.32%

Financial performance

How have Organogenesis Holdings's revenue and profit performed over time
Revenue
$433.14M
Gross profit
$326.66M
Operating income
$12.53M
Net income
$4.95M
Gross margin
75.4%
Net margin
1.1%
ORGO's net margin has dropped by 68% year-on-year and by 62% since the previous quarter
The net income has plunged by 68% YoY and by 62% from the previous quarter
Organogenesis Holdings's operating income has decreased by 45% from the previous quarter and by 44% YoY
Organogenesis Holdings's operating margin has decreased by 42% QoQ and by 41% YoY

Growth

What is Organogenesis Holdings's growth rate over time

Valuation

What is Organogenesis Holdings stock price valuation
P/E
62.25
P/B
1.18
P/S
0.75
EV/EBIT
27.31
EV/EBITDA
9.54
EV/Sales
0.79
The EPS has dropped by 67% year-on-year and by 60% since the previous quarter
The price to earnings (P/E) is 28% more than the last 4 quarters average of 48.7
The P/B is 87% below the 5-year quarterly average of 9.1 and 21% below the last 4 quarters average of 1.5
ORGO's equity is up by 4.9% YoY
ORGO's P/S is 64% below its 5-year quarterly average of 2.1 and 17% below its last 4 quarters average of 0.9
The company's revenue fell by 3.9% YoY and by 3.5% QoQ

Efficiency

How efficient is Organogenesis Holdings business performance
Organogenesis Holdings's return on equity has shrunk by 70% YoY and by 63% QoQ
The ROA has plunged by 69% YoY and by 62% from the previous quarter
The return on invested capital has declined by 47% year-on-year and by 45% since the previous quarter
The return on sales has declined by 42% since the previous quarter and by 41% year-on-year

Dividends

What is ORGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORGO.

Financial health

How did Organogenesis Holdings financials performed over time
ORGO's total assets is 154% greater than its total liabilities
The quick ratio has declined by 10% year-on-year
The current ratio has contracted by 6% YoY
ORGO's debt is 57% smaller than its equity
The debt to equity is down by 9% year-on-year and by 2.3% since the previous quarter
ORGO's equity is up by 4.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.